+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Healthcare Contract Development and Manufacturing Organization (CDMO) Market 2020-2026

  • PDF Icon

    Report

  • June 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5129865
UP TO OFF until Dec 31st 2022
Global Healthcare Contract Development And Manufacturing Organization (CDMO) Market Size, Share & Trends Analysis Report by Services (Contract Development and Contract Manufacturing) and Forecast 2020-2026
The global healthcare CDMO market is estimated to grow significantly during the forecast period. The market growth mainly backed by the various factors such as growing adoption of contract manufacturing and contract development services by the pharmaceutical and medical device companies. As biopharmaceutical companies are significantly investing in R&D, there is a significant scope for manufacturing capacity for pharmaceutical products. Further, the partnerships among pharmaceutical companies and API contract manufacturers were reported. For instance, in January 2018, AstraZeneca PLC entered into a long-term supply agreement with Cambrex Corp., a small generic API manufacturer and molecule innovator. As per the agreement, Cambrex would provide customized API contract manufacturing services to AstraZeneca. Moreover, with the growing pressure over pharmaceutical companies to meet the stringent government regulation while the pharmaceuticals production is encouraging the demand for outsourcing services in pharmaceutical industry that further propels the market growth.

The global market for healthcare CDMO is segregated on the basis of services and region. Based on services, the market is further classified into contract development and contract manufacturing. The contract manufacturing services segment I projected to have significant share in the global healthcare CDMO market owing to the significant adoption of outsourcing services by the pharmaceutical companies across the globe. Based on geography, the global healthcare CDMO market is further segregated into North America, Europe, Asia-Pacific and the Rest of the World. Among, region North America projected to have a considerable share in the global healthcare CDMO market owing to presence of major market players and significant investment in drug discovery and development in the region.

The companies which are contributing to the growth of the global healthcare CDMO market include Catalent, Inc., Lonza Group Ltd., Boehringer Ingelheim International GmbH, Pfizer Inc., Thermo Fisher Scientific Inc., and others. Product launch, merger, and acquisition, collaborations with government, and technological advancements through which market players are considerably contributing to the market growth to stay competitive in the market.

Research Methodology

The market study of the global healthcare CDMO market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for pharmaceutical and medical devices companies for overall market analysis, and competitive analysis. The report provides an in-depth analysis of pricing, market size, intended quality of the product preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.

Market Segmentation:

1. Global Healthcare CDMO Market Research and Analysis by Services

The Report Covers
  • Comprehensive research methodology of the global healthcare CDMO market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global healthcare CDMO market.
  • Insights about market determinants which are stimulating the global healthcare CDMO market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Catalent, Inc.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Lonza Group Ltd.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Boehringer Ingelheim International GmbH
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Pfizer Inc.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Thermo Fisher Scientific Inc.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Healthcare CDMO Market by Services
5.1.1. Contract Development
5.1.1.1. Clinical
5.1.1.2. Preclinical
5.1.1.3. Laboratory Services
5.1.2. Contract Manufacturing
5.1.2.1. Active Pharmaceutical Ingredients( API)
5.1.2.2. Finish Dosage Formulations
5.1.2.3. Medical Devices
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AbbVie Inc.
7.2. Almac Group Ltd.
7.3. Baxter International, Inc.
7.4. B. Braun Melsungen AG
7.5. Boehringer Ingelheim International GmbH
7.6. Catalent Inc.
7.7. Covance Inc.
7.8. Cambrex Corp.
7.9. Hisun Pharmaceuticals Inc.
7.10. Jabil Inc.
7.11. Jubilant Life Sciences Ltd.
7.12. Lonza Group Ltd.
7.13. Mikart LLC
7.14. Pfizer Inc.
7.15. Probiogen AG
7.16. Recipharm AB
7.17. Siegfried Holding AG
7.18. Sanmina Corp.
7.19. Stason Pharmaceuticals, Inc.
7.20. Thermo Fisher Scientific Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie Inc.
  • Almac Group Ltd.
  • Baxter International, Inc.
  • B. Braun Melsungen AG
  • Boehringer Ingelheim International GmbH
  • Catalent Inc.
  • Covance Inc.
  • Cambrex Corp.
  • Hisun Pharmaceuticals Inc.
  • Jabil Inc.
  • Jubilant Life Sciences Ltd.
  • Lonza Group Ltd.
  • Mikart LLC
  • Pfizer Inc.
  • Probiogen AG
  • Recipharm AB
  • Siegfried Holding AG
  • Sanmina Corp.
  • Stason Pharmaceuticals, Inc.
  • Thermo Fisher Scientific Inc.